Hatch-Waxman and Biosimilars Practice Group Leader Sailesh Patel was featured on the ongoing Biologics Price Competition and Innovation Act (BPCIA) Litigation he is watching.
Hatch-Waxman and Biosimilars Practice Group Leader Imron Aly examines how current Hatch-Waxman legal proceedings can be applied to Biologics Price Competition and Innovation Act (BPCIA) litigation.
Schiff Hardin is pleased to announce that four practice areas and 22 attorneys have been recognized in the 2018 edition of Chambers USA, a leading legal industry ranking.
Hatch-Waxman and Biosimilars Practice Group Leader Imron Aly forecast the significance of the U.S. Supreme Court ruling in Oil States Energy Services, LLC, v Greene’s Energy Group, LLC, and how it could impact future patent challenge cases.
Arent Fox is pleased to announce the launch of a new Blockchain group that pulls together attorneys from a number of the firm’s top practices to help clients navigate this emerging technology.
Arent Fox Partner Wib Chesser, in an article published in the April 2018 issue of Intellectual Property Magazine, offers best practices to companies as they enter a business transaction.
This Special Report is written by Helen Ji, Schiff Hardin LLP associate, Rekha Hanu, executive director and chief IP counsel at Akorn Pharmaceuticals, and Christine Simmon, SVP for policy and strategic alliances at the Association for Accessible Medicines.
Partner Kevin Nelson was quoted on the Knowledge Ecology International’s urging of the National Institutes of Health (NIH) to leverage the Bayh-Dole Act in order to combat rising drug prices.
Like generic drugs in the 1980s, biosimilars today face a number of regulatory, legal, scientific, and public perception obstacles to continued growth.
This past November, the US Supreme Court heard oral arguments in a case that may dramatically affect how patents covering biologic drugs are litigated: Oil States Energy Services, LLC v Greene’s Energy Group, LLC.
This year brought us very significant changes in patent jurisprudence from the Supreme Court and Federal Circuit affecting Chemical & Life Sciences patent practice.
Twenty-two Arent Fox LLP practices have been recognized in the 2018 “Best Law Firms” rankings that are published annually by U.S. News & World Report and Best Lawyers.
Four Arent Fox attorneys participated in the ChIPs’ Women in Tech, Law, & Policy Global Summit, which seeks to help women network and advance their careers in technology, law, and policy.
Arent Fox LLP recently served as outside counsel to Rakuten Inc. in a multi-year partnership with the Golden State Warriors and the National Basketball Association.
Craig Gelfound has once again been honored by the Daily Journal as one of the Top Intellectual Property Lawyers in California, with 2017 marking his seventh consecutive year of this recognition.
On July 18, 2017, FDA held a public meeting to address efforts to ensure a balance between innovation in drug development and accelerating the access of the public to lower-cost alternatives to innovator drug therapies is maintained under the Drug Price Competition and Patent Term Restoration Act.
On June 21, the Food and Drug Administration announced a Drug Competition Action Plan in order to attempt to address ways that the agency’s rules have been, in the agency’s view, “gamed” to create obstacles that delay generic drug approvals to reduce generic competition.
The 2017 edition of Legal 500 US has rated 50 Arent Fox LLP attorneys as national leaders in their field. In addition, 17 of the firm’s practice areas were ranked among the best in the country. Legal 500 highlighted Arent Fox’s extensive capabilities across a number of areas of the law.
On May 30, 2017, the Supreme Court issued a landmark 8-0 decision holding that when a patentee sells one of its products, the patentee can no longer control that item through the patent laws.